Karnataka seeks wider medical device price controls as it flags unfair trade margins and rising healthcare costs for patients.
An FDA panel backed GRAIL's Galleri test, raising big questions for liquid biopsy and India's cancer care.
Regulatory radar tracks mixed USFDA outcomes as Glenmark and Dishman clear inspections, while Piramal and Cohance face Form-483 observations.
Roche’s obesity drug enicepatide, shows strong treatment persistence in diabetes patients, delivering 15.5 percent weight loss and significant blood-sugar control at 48 weeks.
World Alzheimer’s Day 2026 highlights why early diagnosis matters as new Alzheimer’s treatments emerge and timely care becomes increasingly important.
Novo Nordisk loses its obesity-drug lead as Lilly gains ground, raising questions over pipeline depth, patent expiry and future growth.
Science still finds insufficient evidence to support stem cell therapy as standard care for autism, keeping the treatment within clinical trials.
India's 'Pharmacy of the World' tag faces fresh scrutiny as a Supreme Court PIL seeks stronger action against fake drugs, counterfeit medicines, and enforcement gaps.
Hospital consumables could be next in line for NPPA price control as regulators examine steep markups and growing calls for structured price monitoring.
AI-backed cancer care gains international attention as India-built iOncology.ai earns recognition at BRICS while moving toward clinical validation.
.jpg)
, CDSCO.jpg)